News

PipelineReview.com4h
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
ISELIN, NJ, USA I April 08, 2025 I Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for ...
PipelineReview.com4h
NexThera Completes First Patient Enrollment in U.S. Clinical Trial for ‘NT-101,’ an Eye Drop Treatment for Wet AMD
BUSAN, South Korea I April 09, 2025 I NexThera Co., Ltd. (CEO:SaeGwang Park) announced on April 9th that it has completed the first patient enrollment for its ...
PipelineReview.com4h
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
SAINT HERBLAIN, France and SCHLIEREN, Zurich I April 9, 2025 I Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech ...
PipelineReview.com4h
Cytora Reports Successful Results of Phase 1/2a Trial of Stem Cell Treatment for Diabetic Foot Ulcers
Cytora's proprietary oral mucosa stem cells treatment holds potential to be a game changer in the field of stem cell therapy ...
PipelineReview.com3h
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis
YANTAI, China I April 8, 2025 I On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and ...
PipelineReview.com4h
Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer
OXFORD, UK I April 9, 2025 I Infinitopes Ltd today announces that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Clinical Trial ...
PipelineReview.com4h
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – ...
PipelineReview.com3h
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
This milestone marks Context’s second active clinical trial, following the dosing of the first patient in the CTIM-76 trial earlier this year. CTIM-76 is a Claudin 6 (“CLDN6”) x CD3 TCE bispecific ...
PipelineReview.com2d
Leyden Labs Publishes New Data Confirming Potential of Intranasal Antibody Approach
LEIDEN, The Netherlands I April 08, 2025 I Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced the publication of new findings that ...
PipelineReview.com2d
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
PARSIPPANY, NJ, USA and INCHEON, Korea I April 07, 2025 I Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), ...
PipelineReview.com2d
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
SOUTH SAN FRANCISCO, CA, USA I April 07, 2025 I ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology ...
PipelineReview.com2d
Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention
MUNICH, Germany & BASEL, Switzerland I April 07, 2025 I Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and ...